N-PORT filing recap · October 2024

What did ARK Genomic Revolution ETF buy in October 2024?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.17B

Positions

Estimated turnover

21.1%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Period in review

ARK Genomic Revolution ETF opened a new position in Illumina and exited Teladoc Health, Uipath, Verve Therapeutics, and Ginkgo Bioworks. It also added substantially to Guardant Health and dramatically to Natera, while trimming Caredx, Vertex Pharmaceuticals, Exact Sciences, and Standard Biotools significantly.

New positions

ILMNIllumina, Inc.$6.05Mreported value+42.0K shares

Increased positions

CRSPCrispr Therapeutics AG$82.65Mreported value+12.9K shares+0.7%RXRXRecursion Pharmaceuticals, Inc.$81.00Mreported value+3.15M shares+32.5%TXG10x Genomics, Inc.$44.71Mreported value+194.9K shares+7.5%NTRANatera, Inc.$44.07Mreported value+200.2K shares

Reduced positions

TWSTTwist Bioscience Corporation$98.39Mreported value-121.1K shares-4.7%CDNACaredx, Inc.$59.67Mreported value-2.17M shares-44.6%ADPTAdaptive Biotechnologies Corporation$54.48Mreported value-763.7K shares-6.4%VCYTVeracyte, Inc.$54.26Mreported value-359.2K shares

Exited positions

VERVVerve Therapeutics, Inc.$16.86Mprior reported value-2.41M shares-100.0%TDOCTeladoc Health, Inc.$12.46Mprior reported value-1.32M shares-100.0%DNAGinkgo Bioworks Holdings, Inc.$7.89Mprior reported value-20.76M shares-100.0%PATHUipath, Inc.$1.3Kprior reported value-105 shares